Johnson & Johnson Financials

Johnson & Johnson

JNJNYSE

Trade with Public

$253.48

-2.08-0.81%

Últ. Act.: Oct 19, 12:40 PM

$252.82

-2.74-1.07%

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Ganancias: Los beneficios de Q3 2026 se publicaron el mar oct 13th, antes de la apertura del mercado

Conferencia telefónica: La conferencia telefónica más reciente comenzó a las 8:30 a. m., hace 6 días

Haz clic para ver el webcast

Johnson & Johnson Financials

Johnson & Johnson (JNJ) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends.

Priya Nigam

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets.

Avi Kapoor

Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.

Vandana Singh

QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

Johnson & Johnson beat third-quarter profit estimates and raised its 2026 forecast. After MedTech sales missed estimates, the stock still fell about 6%, its steepest one-day drop since April 1, 2025. XLV fell 1.1%.

Piero Cingari

Earnings Scheduled For October 13, 2026

Companies Reporting Before The Bell • Unity Bancorp (NASDAQ:UNTY) is likely to report quarterly earnings at $1.55 per share on revenue of $35.60 million. • JPMorgan Chase (NYSE:JPM) is projected to report quarterly

Benzinga Insights

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est

Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 analyst estimate. Raises FY2026 sales outlook from $100.800 billion-$101.400 billion to $101.000

Benzinga Newsdesk

Johnson & Johnson

Johnson & Johnson Financials

Earnings & Guidance News

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

Earnings Scheduled For October 13, 2026

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Johnson & Johnson Financials

Earnings & Guidance News

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

Earnings Scheduled For October 13, 2026

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est

Johnson & Johnson

Johnson & Johnson Financials

Earnings & Guidance News

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

Earnings Scheduled For October 13, 2026

PROJohnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Johnson & Johnson Financials

Earnings & Guidance News

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

Earnings Scheduled For October 13, 2026

PROJohnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est

PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est